EGFR-Mutationsanalyse beim nichtkleinzelligen Lungenkarzinom

Bilello KS, Murin S, Matthay RA (2002) Epidemiology, etiology and prevention of lung cancer. Clin Chest Med 23:1–25

Boldrini L, Gisfredi S, Ursino S et al (2007) Mutational analysis in cytological specimens of advanced lung adenocarcinoma: a sensitive method for molecular diagnosis. J Thorac Oncol 2:1086–1090

Ciardiello F, Tortora G (2008) EGFR antagonists in cancer treatment. N Engl J Med 358:1160–1174

Crino L, Foglietta J, Hamzaj A (2007) Lung cancer. J Thorac Oncol 2:S24–S26

D’addario G, Rauch D, Stupp R et al (2008) Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03. Ann Oncol 19:739–745

Eberhard DA, Giaccone G, Johnson BE (2008) Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. J Clin Oncol 26:983–994

Eberhard DA, Johnson BE, Amler LC et al (2005) Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 23:5900–5909

Engelman JA, Zejnullahu K, Mitsudomi T et al (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316:1039–1043

Grossi F, Aita M, Follador A et al (2007) Sequential, alternating and maintenance/consolidation chemotherapy in advanced non-small cell lung cancer: a review of the literature. Oncologist 12:451–464

Janne PA (2008) Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours. Lung Cancer 60 (Suppl 2):S3–S9

Ladanyi M, Pao W (2008) Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond. Mod Pathol 21 (Suppl 2):S16–S22

Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129–2139

Marchetti A, Felicioni L, Buttitta F (2006) Assessing EGFR mutations. N Engl J Med 354:526–528

Missero C, Pirro MT, Di Lauro R (2000) Multiple ras downstream pathways mediate functional repression of the homeobox gene product TTF-1. Mol Cell Biol 20:2783–2793

Murray S, Timotheadou E, Linardou H et al (2006) Mutations of the epidermal growth factor receptor tyrosine kinase domain and associations with clinicopathological features in non-small cell lung cancer patients. Lung Cancer 52:225–233

Paez JG, Janne PA, Lee JC et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497–1500

Riely GJ (2008) Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. J Thorac Oncol 3:S146–S149

Savic S, Tapia C, Grilli B et al (2008) Comprehensive epidermal growth factor receptor gene analysis from cytological specimens of non-small-cell lung cancers. Br J Cancer 98:154–160

Schutze K, Niyaz Y, Stich M et al (2007) Noncontact laser microdissection and catapulting for pure sample capture. Methods Cell Biol 82:649–673

Sequist LV, Bell DW, Lynch TJ et al (2007) Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol 25:587–595

Sharma SV, Bell DW, Settleman J et al (2007) Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7:169–181

Shigematsu H, Lin L, Takahashi T et al (2005) Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97:339–346

Smith GD, Chadwick BE, Willmore-Payne C et al (2008) Detection of epidermal growth factor receptor gene mutations in cytology specimens from patients with non-small cell lung cancer utilising high-resolution melting amplicon analysis. J Clin Pathol 61:487–493

Tsao AS, Tang XM, Sabloff B et al (2006) Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer. J Thorac Oncol 1:231–239

Tsao MS, Sakurada A, Cutz JC et al (2005) Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 353:133–144

Yamamoto H, Toyooka S, Mitsudomi T (2008) Impact of EGFR mutation analysis in non-small cell lung cancer. Lung Cancer 315–321

Yatabe Y, Kosaka T, Takahashi T et al (2005) EGFR mutation is specific for terminal respiratory unit type adenocarcinoma. Am J Surg Pathol 29:633–639

Yatabe Y, Takahashi T, Mitsudomi T (2008) Epidermal growth factor receptor gene amplification is acquired in association with tumor progression of EGFR-mutated lung cancer. Cancer Res 68:2106–2111

Zhang X, Chang A (2008) Molecular predictors of EGFR-TKI sensitivity in advanced non-small cell lung cancer. Int J Med Sci 5:209–217

Zhu CQ, Da Cunha Santos G, Ding K et al (2008) Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 26:4268–4275